Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Relmada Therapeutics, Inc.

NASDAQ: RLMD · Life Sciences · 3 alerts · CIK 1553643

Share price
$3.61Close, Nov 16
Market cap
$385M
Shares outstanding
106.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Relmada Therapeutics, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Leadership Change

Relmada Therapeutics Leadership Change

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.